Skip to main content
Premium Trial:

Request an Annual Quote

MiTeGen, EMBLEM Sign Structural Biology Agreements

NEW YORK (GenomeWeb News) – Structural biology tools firm MiTeGen announced today it has forged development and distribution agreements with EMBLEM, the commercial subsidiary of the European Molecular Biology Laboratory.

MiTeGen and EMBL's operations in Grenoble, France, are collaborating on the further development of thin-film crystallization plates for protein crystallization. Also, MiTeGen will exclusively distribute on a worldwide basis EMBL's CrystalDirect plates as well as non-exclusively distribute other EMBL products, including the SC3 basket for cryo-storage and transport of samples, MiTeGen said.

Financial and other terms of the deal were not disclosed.

"The development of thin-film plates such as MiTeGen's In-Situ-01 plate, and EMBL's CrystalDirect Plate brings significant new capabilities to crystallographers," including the ability to perform X-ray and UV studies on crystals in situ, Robert Newman, CEO of MiTeGen, said in a statement. "The collaboration of MiTeGen and the EMBL for the further development in this arena is a great match for bringing unique advancements in these tools to the scientific community."

MiTeGen, based in Ithaca, NY, designs, manufactures, and distributes products for crystallization, crystallography, and X-ray diffraction of proteins, viruses, and small molecule and inorganic compounds, it said. Additionally, the company develops and distributes products for manipulating and measuring small samples in cell biology, histology, clinical diagnostics, entomology, archaeology, art restoration, and geology.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.